PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Sixteen New Catalog Peptides - This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced sixteen (16) new catalog peptides
AnaSpec Introduces Sixteen New Catalog Peptides


NewswireToday - /newswire/ - San Jose, CA, United States, 2007/12/18 - This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced sixteen (16) new catalog peptides.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


[Cys17]-beta-Amyloid (1-17)- Cat# 62473
This peptide amino acids 1 to 17 is a modified fragment of the b-amyloid peptide; with cysteine substituted for valine at position 17.

[Cys24]-beta-Amyloid (1-24)- Cat# 62475
This peptide with amino acids 1 to 24 is a modified fragment of the b-amyloid peptide; with cysteine substitution for valine at position 24.

Beta-Amyloid (1-16)-Lys(Biotin-LC)-NH2- Cat# 62136
This is the N-terminal fragment of the b-amyloid peptide; residues 1 to 17; biotinylated on the lysine side chain with 6-aminohexanoate (LC) as a spacer.

Beta-Amyloid (1-16)-Lys(LC-Biotin)-NH2- Cat# 62464
This is amino acids 1 to 17 N-terminal fragment of the b-amyloid peptide with 6-aminohexanoate (LC) as a spacer on the side chain of lysine; and biotinylated

Beta-Amyloid (1-28)-Lys (Biotin)- Cat# 62465
This is amino acids 1 to 28 fragment of the b-amyloid peptide biotinylated on the side chain of lysine

Beta-Amyloid (22-40)- Cat# 62453
This is amino acids 22 to 40 fragment of the ß-?amyloid peptide. This sequence may be used in the ß-?amyloid structure and aggregation studies.

Beta-Amyloid (25-35); biotinylated- Cat# 62451
This peptide is amino acids 25 to 35 fragment of the ß-amyloid; biotinylated at C-terminus. This peptide possesses many of the characteristics of the full-length ß-amyloid peptide; including an amphiphilic nature and an ability to aggregate; and can serve as a model system to study the conformational changes involved in Alzheimer's disease. Aggregates of ß-amyloid (25–35) have been shown to possess the neurotrophic and neurotoxic properties of their full-length counterparts and there is evidence that the monomeric form of the peptide may itself be cytotoxic.
Sequence: Biotin-GSNKGAIIGLM

Galanin Like Peptide (GALP); rat- Cat# 61847-05
This 60-amino acid rat Galanin Like Peptide (GALP) has homology with human and porcine GALP. GALP peptide was first isolated from the porcine hypothalamus; and then identified in other species including rats and humans. It shows GALR2-agonistic activity; and induces food intake. Studies show the importance of hypothalamic GALP in the integration of metabolism and reproduction.

RAB38/NY-MEL-1 (50-58)- Cat# 62367
This is amino acids 50 to 58 fragment of the melanocyte differentiation antigen RAB38/NY-MEL-1 protein which is expressed in the vast majority of melanoma lesions. The immunogenicity of RAB38/NY-MEL-1 has been corroborated by the frequent occurrence of specific antibody responses in melanoma patients. This peptide exhibits a marked response in ELISPOT assays after in vitro sensitization of CD8 T cells from HLA-A*0201+ melanoma patients.

PB2 (198–206) Polymerase Mimotope- Cat# 62259
This peptide is derived from the PB2 polymerase (PB2198–206). PB2198 is a mimotope that can stimulate an IFN-gamma. response by highly activated PB1703-specific CD8+ T cells and is recognized by PB1703-specific CTL. It is not capable of driving either the clonal expansion of cells that bind the KbPB1703- tetramer or effector CTL generation following in vitro culture.

Measles Virus Fusion Protein (421–435)- Cat# 62409
This peptide is amino acid 421 to 435 fragment of the measles virus fusion protein (MV-F). It is an immunodominant Ta; H2d restricted epitope; it induces MV-specific T lymphocytes in vivo.

[pTyr429] Erythropoietin Receptor Peptide (EpoR); (423-438)- Cat# 62345
This is amino acid 423 to 438 fragment of the Erythropoietin Receptor Peptide (EpoR); phosphorylated at Tyr429. It binds to the N-SH2 domain that has a function in regulation of the PTPase domain and thereby signal transduction. It activates SHP-1 (previously called PTP1C; HCP; and SHPTP1); a protein-tyrosine phosphatase with two Src homology 2 (SH2) domains predominantly expressed in hematopoietic cells.

MAGE-A1 Antigen (278-286); human- Cat# 62365
This peptide is amino acids 278 to 286 fragment of MAGE protein. It was found to be presented by HLA-A 0201 molecules on the surface of a human breast carcinoma cell line. MAGE-A1 tumor antigen can fully activate the mouse peptide-specific CTL lines to produce IFN-gamma. Tumor-specific shared antigens; such as those of the MAGE gene family; are expressed by tumors of different histological types.

p53 (17-26)- Cat# 61375
This peptide is amino acids 17 to 26 fragment of p53; the Mdm-2 binding domain of p53 known also as p53N. This sequence contains all of the residues that contact the binding domain of Mdm-2. The tumor suppressor protein p53 is important in maintaining genome stability and in preventing cancer development.

Myelopeptide-1 (MP-1)- Cat# 62362
This immunoregulatory peptide was originally isolated from the conditioned medium of porcine bone marrow cell cultures. Myelopeptide-1 blocks the T-suppressor activity. It enhances the number of antibody-forming cells in mouse spleen cells in vitro and increases antibody production in (CBAxC57B1/6)F1 mice in vivo.
Sequence: FLGFPT

Insulin Growth Factor Binding Protein 6 (IGFBP6); human- Cat# 62417
This decapeptide belongs to the human insulin growth factor (IGF) binding protein 6 (IGFBP6). There are six well-characterized IGFBPs. They are not only carriers of IGFs; but also modulators of their activity. IGFBPs are important in cell growth.

About AnaSpec, Inc.
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: AnaSpec, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

AnaSpec Introduces Sixteen New Catalog Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Albert Olson Hong 
1-408-452-5055 ping[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From AnaSpec, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  S&A Capital Partner Ltd

Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (